Leuko

Boston, United States Founded: 2017 • Age: 9 yrs
Manufacturer of WBC monitoring device

About Leuko

Leuko is a company based in Boston (United States) founded in 2017 by Carlos Castro Gonzalez, Alvaro Sanchez-Ferro, Aurelien Bourquard, and Ian Butterworth.. Leuko has raised $6.8 million across 4 funding rounds from investors including NIH, HHS and Good Growth Capital. Leuko offers products and services including PointCheck and A.I. Algorithms.

  • Headquarter Boston, United States
  • Founders Carlos Castro Gonzalez, Alvaro Sanchez-Ferro, Aurelien Bourquard, Ian Butterworth
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Leuko Labs Inc
Operational Areas
Healthcare → Medical Devices & Diagnostics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $6.8 M (USD)

    in 4 rounds

  • Latest Funding Round
    $4.5 M (USD), Grant

    Jul 23, 2024

  • Investors
    NIH

    & 6 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Leuko

Leuko offers a comprehensive portfolio of products and services, including PointCheck and A.I. Algorithms. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

A device is developed for non-invasive monitoring of white blood cell levels, intended for use in home environments to assess infection risks.

Algorithms are employed to analyze blood cell data captured by the device, aiding in the determination of elevated infection risks.

Funding Insights of Leuko

Leuko has successfully raised a total of $6.8M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $4.5 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Grant — $4.5M
  • First Round

    (12 Jul 2018)

  • Investors Count 7
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2024 Amount Grant - Leuko Valuation

investors

NIH
Sep, 2022 Amount Series A - Leuko Valuation

investors

Feb, 2019 Amount Seed - Leuko Valuation Good Growth Capital
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Leuko

Leuko has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Good Growth Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
HTH is engaged in investing in health technology startups.
Founded Year Domain Location
Early-stage investments are made in life sciences and technologies.
Founded Year Domain Location
Venture capital investments are provided by IAG Capital Partners.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Leuko

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Leuko

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Leuko Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Leuko

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Leuko

Frequently Asked Questions about Leuko

When was Leuko founded?

Leuko was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Leuko located?

Leuko is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Who is the current CEO of Leuko?

Carlos Castro Gonzalez is the current CEO of Leuko. They have also founded this company.

Is Leuko a funded company?

Leuko is a funded company, having raised a total of $6.8M across 4 funding rounds to date. The company's 1st funding round was a Seed of $1.8M, raised on Jul 12, 2018.

What does Leuko do?

Leuko was founded in 2017 and is headquartered in Boston, United States. Operations focus on the medical device sector, where a non-invasive device for monitoring white blood cell counts is developed and produced. This technology supports hematology diagnostics in healthcare settings. The company was established by co-founders including Carlos Castro Gonzalez as CEO, Alvaro Sanchez-Ferro, Aurelien Bourquard, and Ian Butterworth. Activities are centered on advancing point-of-care testing solutions. (68 words).

What products or services does Leuko offer?

Leuko offers PointCheck and A.I. Algorithms.

Who are Leuko's investors?

Leuko has 7 investors. Key investors include NIH, HHS, Good Growth Capital, HTH, and IAG Capital Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available